Abstract Modern multimodal oncology foundation models (OFMs) can predict patient trajectories and simulate treatment effects from clinical, genomic, transcriptomic, and histologic data, but they remain largely black boxes: they rarely explain which mechanisms drive risk or how to modulate those mechanisms with feasible interventions. We trained a multimodal OFM on over 1.2 million cancer patients with longitudinal clinical records, tumor DNA and RNA sequencing, and H Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1467.
Schadt et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: